The Technical Analyst
Calithera Biosciences Inc [CALA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Calithera Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-37.38% $0.0251
America/New_York / 18 apr 2024 @ 14:55
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.122 mill |
| EPS: | -7.94 |
| P/E: | 0 |
| Earnings Date: | Mar 29, 2024 |
| SharesOutstanding: | 4.87 mill |
| Avg Daily Volume: | 0.0012 mill |
| RATING 2024-04-18 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0211 - 0.0291 ( +/- 15.97%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-04-17 | Takeda Pharmaceutical Co Ltd | Sell | 1 000 000 | Series A Convertible Preferred Stock |
| 2023-01-27 | Pakianathan Deepika | Sell | 1 172 | Common Stock |
| 2023-01-23 | Sjogren Eric | Sell | 279 | Common Stock |
| 2023-01-23 | Kuriakose Emil | Sell | 79 | Common Stock |
| 2023-01-23 | Molineaux Susan | Sell | 526 | Common Stock |
| INSIDER POWER |
|---|
| -48.06 |
| Last 99 transactions |
| Buy: 6 839 475 | Sell: 3 539 228 |
Forecast:
16:00 - $0.0251
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0251 (-37.38% ) |
| Volume | 0.0011 mill |
| Avg. Vol. | 0.0012 mill |
| % of Avg. Vol | 88.48 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CALA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CALA
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Last 10 Buy Signals
Latest Press Releases
2022-11-08 16:30:00 - Press Release
Calithera Biosciences To Report Third Quarter 2022 Financial Results On Monday, November 14, 2022
South san francisco, calif., nov. 08, 2022 (globe newswire) -- calithera biosciences, inc. (nasdaq: cala), a clinical-stage, precision-oncology biopharmaceutical company, today announced company's third quarter 2022 financial results will be released on monday, november 14, 2022. company management will host a conference call on monday, november 14, 2022, at 2:00 p.m. pacific time / 5:00 p.m. eastern time to discuss the financial results and other recent corporate highlights.
2022-09-06 16:05:00 - Press Release
Calithera To Present At The H.c. Wainwright 24th Annual Global Investment Conference
South san francisco, calif., sept. 06, 2022 (globe newswire) -- calithera biosciences, inc. (nasdaq: cala), a clinical-stage, precision oncology biopharmaceutical company, today announced that susan molineaux, ph.d., the company's founder, president and chief executive officer, will present at the h.c. wainwright 24th annual global investment conference, being held september 12-14 both virtually and in new york, ny.
2022-05-17 07:00:00 - Press Release
Calithera To Present At The H.c. Wainwright Global Investment Conference
South san francisco, calif., may 17, 2022 (globe newswire) -- calithera biosciences, inc. (nasdaq: cala), a clinical-stage, precision oncology biopharmaceutical company, today announced that susan molineaux, ph.d., the company's founder, president and chief executive officer, will present at the h.c. wainwright global investment conference, being held may 23-25 both virtually and in miami, fl.
2022-05-03 16:05:00 - Press Release
Calithera Biosciences To Report First Quarter 2022 Financial Results On Tuesday, May 10, 2022
South san francisco, calif., may 03, 2022 (globe newswire) -- calithera biosciences, inc. (nasdaq: cala), a clinical-stage, precision oncology biopharmaceutical company, today announced that the company's first quarter 2022 financial results will be released on tuesday, may 10, 2022. company management will host a conference call on tuesday, may 10, 2022, at 2:00 p.m. pacific time / 5:00 p.m. eastern time to discuss the financial results and other recent corporate highlights.
2022-03-24 07:00:00 - Press Release
Calithera Biosciences To Report Fourth Quarter And Full Year 2021 Financial Results On Thursday, March 31, 2022
South san francisco, calif., march 24, 2022 (globe newswire) -- calithera biosciences, inc. (nasdaq: cala), a clinical-stage, precision oncology biopharmaceutical company, today announced that the company's fourth quarter and full year 2021 financial results will be released on thursday, march 31, 2022. company management will host a conference call on thursday, march 31, 2021 at 2:00 p.m. pacific time/ 5:00 p.m. eastern time to discuss the financial results and other recent corporate highlights.
Latest News
2022-11-14 22:17:24 - Seeking Alpha
Calithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call Transcript
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q3 2022 Earnings Conference Call November 14, 2022 5:00 PM ET Company Participants Stephanie Wong - CFO & Secretary Susan Molineaux - Founder, CEO, President & Director Emil Kuriakose - Chief Medical Officer Conference Call Participants Jiale Song - Jefferies Swayampakula Ramakanth - H.C. Wainwright & Co. Matthew Cowper - SVB Securities Aydin Huseynov - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and thank you for standing by.
2022-11-08 16:30:00 - GlobeNewsWire
Calithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company's third quarter 2022 financial results will be released on Monday, November 14, 2022. Company management will host a conference call on Monday, November 14, 2022, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
2022-10-03 09:08:44 - Market Watch
Calithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidate
Shares of Calithera Biosciences Inc. CALA, -0.68% jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested in Phase 2 clinical trial.
2022-09-09 15:14:46 - InvestorPlace
3 Penny Stocks With Surprisingly Superior Fundamentals
The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks.
2022-09-06 16:05:00 - GlobeNewsWire
Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.
2022-08-15 20:42:05 - Seeking Alpha
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2022 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Stephanie Wong - Chief Financial Officer Susan Molineaux - Founder, President & Chief Executive Officer Emil Kuriakose - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Securities Roger Song - Jefferies Operator Good day, and welcome to the Calithera Biosciences' Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
2022-07-28 12:42:50 - InvestorPlace
What Is a Reverse Stock Split and How Does It Work?
We've seen a spate of stock splits in 2022, including from high-profile companies, such as Amazon (NASDAQ: AMZN ) and Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ). But while a stock split may too familiar for you, a reverse split is not a very common corporate action.
2022-06-27 20:15:10 - InvestorPlace
What is a Reverse Stock Split and How Does it Work?
Reverse stock splits are not that common and often are associated with some trouble brewing at the company. Therefore, one must do a thorough study before deciding what to do what with the stock of a company that just announced a reverse split.
2022-05-17 07:00:00 - GlobeNewsWire
Calithera to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.
2022-05-10 22:04:09 - Seeking Alpha
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2022 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (NASDAQ:CALA ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Susan Molineaux - Founder, President & CEO Stephanie Wong - CFO Emil Kuriakose - Chief Medical Officer Conference Call Participants Jonathan Chang - SVB Leerink Nick Abbott - Wells Fargo Ramakanth Swayampakula - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Ladies and gentlemen, thank you for standing by and welcome to Calithera Biosciences 1Q 2022 Earnings.